BACKGROUND: The insulin-like growth factor system, which includes insulin-like growth factors (IGF-I and IGF-II), IGF receptors (IGF-IR and IGF-IIR) and IGF binding proteins (IGFBPs), plays an important role in epithelial growth, anti-apoptosis and mitogenesis. There is a growing body of evidence showing that IGFs control growth and proliferation of several types of cancer. This review introduces the latest information on the biology of the IGF system and its pathophysiological role in the development of colorectal cancer. DISCUSSION: The growth promoting effects of IGF-I and IGF-II on cancer cells are mediated through the IGF-IR, which is a tyrosine kinase and cancer cells with a strong tendency to metastasise have a higher expression of the IGF-IR. Most of the IGFs in circulation are bound to the IGFBPs, which regulate the bioavailability of the IGFs. All IGFBPs inhibit IGF action by high affinity binding, while some of them also potentiate the effects of IGFs. Colon cancer cells produce specific proteases that degrade the IGFBP so that the IGF will be free to act on the cancer cell in an autocrine manner. Therefore, the IGFBPs play a crucial role in the development of the cancer. CONCLUSION: The current knowledge about the link between IGFs and colon cancer is mainly based on in vitro investigations. Further in vivo study is needed to understand the exact role of the IGF system, especially its binding proteins, so that they can be manipulated for the prevention and treatment of colorectal cancer.
BACKGROUND: The insulin-like growth factor system, which includes insulin-like growth factors (IGF-I and IGF-II), IGF receptors (IGF-IR and IGF-IIR) and IGF binding proteins (IGFBPs), plays an important role in epithelial growth, anti-apoptosis and mitogenesis. There is a growing body of evidence showing that IGFs control growth and proliferation of several types of cancer. This review introduces the latest information on the biology of the IGF system and its pathophysiological role in the development of colorectal cancer. DISCUSSION: The growth promoting effects of IGF-I and IGF-II on cancer cells are mediated through the IGF-IR, which is a tyrosine kinase and cancer cells with a strong tendency to metastasise have a higher expression of the IGF-IR. Most of the IGFs in circulation are bound to the IGFBPs, which regulate the bioavailability of the IGFs. All IGFBPs inhibit IGF action by high affinity binding, while some of them also potentiate the effects of IGFs. Colon cancer cells produce specific proteases that degrade the IGFBP so that the IGF will be free to act on the cancer cell in an autocrine manner. Therefore, the IGFBPs play a crucial role in the development of the cancer. CONCLUSION: The current knowledge about the link between IGFs and colon cancer is mainly based on in vitro investigations. Further in vivo study is needed to understand the exact role of the IGF system, especially its binding proteins, so that they can be manipulated for the prevention and treatment of colorectal cancer.
Authors: P J Jenkins; V Frajese; A M Jones; C Camacho-Hubner; D G Lowe; P D Fairclough; S L Chew; A B Grossman; J P Monson; G M Besser Journal: J Clin Endocrinol Metab Date: 2000-09 Impact factor: 5.958
Authors: R C Baxter; M A Binoux; D R Clemmons; C A Conover; S L Drop; J M Holly; S Mohan; Y Oh; R G Rosenfeld Journal: J Clin Endocrinol Metab Date: 1998-09 Impact factor: 5.958
Authors: Niels Reinmuth; Wenbiao Liu; Fan Fan; Young D Jung; Syed A Ahmad; Oliver Stoeltzing; Corazon D Bucana; Robert Radinsky; Lee M Ellis Journal: Clin Cancer Res Date: 2002-10 Impact factor: 12.531
Authors: Marcia Cruz-Correa; Hengmi Cui; Francis M Giardiello; Neil R Powe; Linda Hylind; Angela Robinson; David F Hutcheon; David R Kafonek; Sheri Brandenburg; Yiqian Wu; Xiaobing He; Andrew P Feinberg Journal: Gastroenterology Date: 2004-04 Impact factor: 22.682
Authors: Eun J Kim; Beverly S Schaffer; Young-hee Kang; Richard G Macdonald; Jung Hy Park Journal: J Gastroenterol Hepatol Date: 2002-05 Impact factor: 4.029
Authors: Akiko Hanyuda; Sun A Kim; Alejandro Martinez-Fernandez; Zhi Rong Qian; Mai Yamauchi; Reiko Nishihara; Teppei Morikawa; Xiaoyun Liao; Kentaro Inamura; Kosuke Mima; Yin Cao; Xuehong Zhang; Kana Wu; Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Charles S Fuchs; Ramesh A Shivdasani; Shuji Ogino Journal: Ann Surg Oncol Date: 2015-11-17 Impact factor: 5.344
Authors: C L Ronchi; F Coletti; E Fesce; L Montefusco; C Ogliari; E Verrua; P Epaminonda; E Ferrante; E Malchiodi; V Morelli; P Beck-Peccoz; M Arosio Journal: J Endocrinol Invest Date: 2009-04-29 Impact factor: 4.256
Authors: Sharon J Pitteri; Samir M Hanash; Aaron Aragaki; Lynn M Amon; Lin Chen; Tina Busald Buson; Sophie Paczesny; Hiroyuki Katayama; Hong Wang; Melissa M Johnson; Qing Zhang; Martin McIntosh; Pei Wang; Charles Kooperberg; Jacques E Rossouw; Rebecca D Jackson; Joann E Manson; Judith Hsia; Simin Liu; Lisa Martin; Ross L Prentice Journal: Genome Med Date: 2009-12-24 Impact factor: 11.117